Merck & Co., Inc. (NYSE:MRK) Shares Climb 3.6% – Here’s Why

Shares of Merck & Co., Inc. (NYSE:MRK) traded up 3.6% during mid-day trading on Wednesday. The company traded as high as $146.67 and last traded at $147.1410. 2,234,501 shares traded hands during trading, a decline of 79% from the average session volume of 10,586,647 shares. The stock had previously closed at $141.98.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present first-time pivotal Phase 3 data at ESMO 2026 for oncology programs including melanoma and endometrial cancer. The company will also hold an oncology investor event, potentially giving investors greater visibility into growth opportunities beyond Keytruda. What Could Merck Reveal At ESMO 2026 About Its Oncology Pipeline?
• Positive Sentiment: CEO Rob Davis said Merck and Moderna expect manufacturing of their personalized cancer vaccine to become faster over time. Improving production efficiency could support broader commercialization of the vaccine, although manufacturing remains complex. Merck CEO Tells CNBC He Expects Breakthrough Cancer Vaccine Will Become Faster to Make
• Neutral Sentiment: Analysts expect Keytruda sales growth, newer product launches and expanded indications to support third-quarter revenue. However, biosimilar competition is expected to become a more significant risk in 2028–2029, making pipeline execution increasingly important. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Neutral Sentiment: Merck’s dividend yield is about 2.3%, but comparisons with Amgen highlight differing levels of dividend coverage and cash-flow flexibility. The analysis may influence income-focused investors but does not introduce a new company-specific catalyst. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Merck trades at a premium valuation of roughly 5.5 times sales, increasing the market’s expectations for sustained growth. Investors are also monitoring the changing emphasis in management’s strategy and continuing challenges for the Gardasil vaccine business in China. How Has Merck’s Story Changed?

Analysts Set New Price Targets

MRK has been the topic of several recent research reports. Wolfe Research lifted their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday, August 25th. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, October 5th. Jefferies Financial Group upped their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Barclays increased their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, CICC Research began coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Stock Performance

The stock’s 50-day moving average price is $145.26 and its 200 day moving average price is $129.12. The firm has a market cap of $359.37 billion, a P/E ratio of 116.53, a price-to-earnings-growth ratio of 6.81 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insider Buying and Selling

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at $17,569,312.29. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last three months. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after buying an additional 1,073,507 shares in the last quarter. State Street Corp increased its holdings in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after buying an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after buying an additional 1,934,312 shares during the last quarter. Bank of America Corp DE raised its position in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. raised its position in Merck & Co., Inc. by 3.5% during the fourth quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock worth $2,162,691,000 after acquiring an additional 701,249 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.